SCHEMBL2297449

SCHEMBL2297449

COc1nc(-c2ccccc2)c(-c2ccccc2)cc1CNc1ccc(SCC(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.47
MALT1 Q9UDY8 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
LMNA P02545 3/20 0.39
THRB P10828 1/20 0.39
CD274 Q9NZQ7 2/20 0.38
PDCD1LG2 Q9BQ51 1/20 0.38
PDCD1 Q15116 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
HIF1A Q16665 1/20 0.37
PABPC1 P11940 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301881 0.89 FFAR1 (0.46) FFAR1KMT2AGAALMNACD274
SCHEMBL2300745 0.82 FFAR1 (0.47) FFAR1GAALMNACD274PDCD1LG2
SCHEMBL2300603 0.82 FFAR1 (0.51) FFAR1KMT2AMEN1GAAFFAR4
SCHEMBL14931901 0.77 FFAR1 (0.38) FFAR1KMT2AMEN1LMNAALDH1A1
SCHEMBL2301765 0.74 FFAR1 (0.63) FFAR1FFAR4
SCHEMBL2298721 0.73 POLB (0.43) FFAR1KMT2AMEN1GAATHRB
SCHEMBL19073494 0.72 HIF1A (0.47) FFAR1KMT2AGAAFFAR4ALDH1A1
SCHEMBL2298014 0.72 FFAR1 (0.41) FFAR1GAAALDH1A1MAPT
SCHEMBL19074174 0.71 FFAR1 (0.71) FFAR1FFAR4HIF1A
SCHEMBL19074085 0.70 FFAR1 (0.69) FFAR1KMT2AMEN1FFAR4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US claimed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP claimed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US claimed
WO-2016149299-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. (US) 2016-09-22 WO disclosed
US-20160271149-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. 2016-09-22 US disclosed
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG FFAR1 10/4885MALT1 4444/4885KMT2A 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.